Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.

Employees

2,799

Sector

Pharmaceuticals

Calendar

Apr. 08 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-01-16	6,300.00 ¥	-0.88%	535,500
26-01-15	6,356.00 ¥	-1.52%	432,700
26-01-14	6,454.00 ¥	+1.33%	555,900
26-01-13	6,369.00 ¥	-1.12%	717,100
26-01-09	6,441.00 ¥	+0.02%	760,100

Delayed Quote Japan Exchange, January 16, 2026 at 01:30 am EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6,300.00JPY

Average target price

4,250.00JPY

Spread / Average Target

-32.54%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 01:30:00 2026-01-16 am EST			5-day change	1st Jan Change
6,300.00 ^JPY	-0.88%		-2.19%	+43.44%

Jan. 16	Takasago to Tender All Hisamitsu Pharma Shares	MT
Jan. 07	Japan's Nikkei slips 1% from record as investors book profit	RE

Capitalization	441B 2.79B 2.41B 2.24B 2.09B 3.89B 253B 4.18B 25.79B 10.17B 121B 10.48B 10.26B	P/E ratio 2026 *	21.1x	P/E ratio 2027 *	27.9x
Enterprise value	441B 2.79B 2.41B 2.24B 2.09B 3.89B 253B 4.18B 25.79B 10.17B 121B 10.48B 10.26B	EV / Sales 2026 *	2.73x	EV / Sales 2027 *	2.68x
Free-Float	61.13%	Yield 2026 *	1.9%	Yield 2027 *	2.02%

Jan. 16	Takasago to Tender All Hisamitsu Pharma Shares	MT
Jan. 07	Japan's Nikkei slips 1% from record as investors book profit	RE
Jan. 06	Japan's Nikkei slips from record closing high, market eyes US jobs data	RE
Jan. 06	Japan's Hisamitsu Pharmaceutical plans $2.55 billion MBO	RE
Jan. 06	Hisamitsu Pharmaceutical Co., Inc. Revises Dividend Guidance for the Fiscal Year Ending February 28, 2026	CI
Jan. 06	Hisamitsu Pharmaceutical Co., Inc. Announces Withdrawal of Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2026	CI
Jan. 05	Hisamitsu Pharmaceutical Co Inc - True that we are considering going private	RE
Jan. 05	Hisamitsu Pharmaceutical's management is considering a takeover bid to privatize the Japanese maker of Salonpas - Bloomberg News	RE
Jan. 05	CEO of Hisamitsu Pharmaceutical Reportedly Seeks to Take $2.9 Billion Firm Private	CI
Jan. 05	Taiyo Kosan Co., Ltd. agreed to acquire a 97.49% stake in Hisamitsu Pharmaceutical Co., Inc. from Takasago International Corporation for approximately ¥380.6 billion in a management buyout transaction.	CI
Nov. 20	Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on July 10, 2025.	CI
Nov. 18	Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback announced on July 10, 2025, has closed with 3,000,000 shares, representing 4.15% for ¥12,269.27 million.	CI
25-10-09	Hisamitsu Pharmaceutical Attributable Profit Falls 23% in Fiscal H1	MT

Jan. 07	Hisamitsu Pharmaceutical : Announcement of Implementation of MBO and Recommendation for Tendering Shares	PU
Jan. 07	Notice Regarding Commencement of Tender Offer by TAIYO KOSAN CO.,INC. for Share Certificates, Etc. of Hisamitsu Pharmaceutical Co., Inc. (Securities Code: 4530)	PU
Jan. 06	Hisamitsu Pharmaceutical : Announcement on Revision of the Dividend Forecast for the Fiscal Year Ending February 28, 2026 (No Dividend)	PU
Jan. 06	Hisamitsu Pharmaceutical : Announcement on Withdrawal of the Earnings Forecast for the Fiscal Year Ending February 28, 2026	PU
Nov. 20	Hisamitsu Pharmaceutical : Notification Regarding Results of Acquisition of Treasury Shares	PU

Hisamitsu Pharmaceutical Co., Inc. Stock

Equities

4530

JP3784600003

Pharmaceuticals

Valuation: Hisamitsu Pharmaceutical Co., Inc.

Chart: Hisamitsu Pharmaceutical Co., Inc.

Latest news: Hisamitsu Pharmaceutical Co., Inc.

Press Releases: Hisamitsu Pharmaceutical Co., Inc.

News in other languages: Hisamitsu Pharmaceutical Co., Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Hisamitsu Pharmaceutical Co., Inc.

ETFs: Hisamitsu Pharmaceutical Co., Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

21-09-03	MÄRKTE ASIEN/Börse in Tokio von Suga-Rückzug beflügelt
13-11-25	Wendel face à Nordic Capital pour LTS Lohmann-sources
13-11-25	Wendel opposé à Nordic Capital pour reprendre LTS Lohmann-sces

1 day	-0.88%
1 week	-2.19%
Current month	+43.44%
1 month	+48.06%
3 months	+56.72%
6 months	+56.76%
Current year	+43.44%

1 week	6,299	6,480
1 month	4,202	6,695
Current year	4,389	6,695
1 year	3,783	6,695
3 years	3,541	6,695
5 years	3,230	7,750
10 years	3,230	9,950

Manager	Title	Age	Since
Kazuhide Nakatomi PSD	President	53	2015-04-30
Takaaki Terahara CTO	Chief Tech/Sci/R&D Officer	-	-
Naruhito Higo CTO	Chief Tech/Sci/R&D Officer	63	-

Director	Title	Age	Since
Kousuke Sugiyama BRD	Director/Board Member	73	1999-04-30
Kazuhide Nakatomi BRD	Director/Board Member	53	2007-04-30
Kyu Saito BRD	Director/Board Member	62	2013-04-30

Name		Varia. Jan 1.	Weight	AuM
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY		+2.59%	0.51%	27 M€
LEVERAGE SHARES PLC - 3X LONG TOTAL WORLD ETP		-.--%	0.04%	1 M€

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
HISAMITSU PHARMACEUTICAL CO., INC.	-0.88%	-2.19%	+37.11%	+63.21%	2.79B
ELI LILLY AND COMPANY	+0.53%	-2.37%	+43.09%	+190.27%	930B
JOHNSON & JOHNSON	-0.41%	+6.98%	+48.72%	+26.86%	527B
ABBVIE INC.	-0.31%	-2.60%	+24.94%	+40.25%	379B
ROCHE HOLDING AG	+0.93%	+2.38%	+31.46%	+18.47%	371B
ASTRAZENECA PLC	+0.19%	-1.15%	+28.47%	+21.14%	292B
NOVARTIS AG	+0.98%	+1.37%	+29.42%	+35.03%	276B
MERCK & CO., INC.	-1.93%	-1.54%	+11.14%	-1.47%	270B
NOVO NORDISK A/S	+6.49%	+1.95%	-32.44%	-18.44%	268B
AMGEN INC.	+0.12%	+1.32%	+21.43%	+22.64%	178B
Average	+0.57%	+0.42%	+24.33%	+39.80%	349.37B
Weighted average by Cap.	+0.59%	+0.50%	+29.06%	+65.22%

	2026 *	2027 *
Net sales	161B 1.02B 881M 820M 763M 1.42B 92.68B 1.53B 9.43B 3.72B 44.21B 3.83B 3.75B	165B 1.04B 898M 836M 778M 1.45B 94.5B 1.56B 9.61B 3.79B 45.08B 3.91B 3.83B
Net income	19.79B 125M 108M 101M 93.58M 174M 11.36B 187M 1.16B 456M 5.42B 470M 460M	15.64B 98.94M 85.3M 79.41M 73.92M 138M 8.98B 148M 913M 360M 4.28B 371M 363M
Net Debt	-	-